MAbSilico is a deeptech company from French academic research labs. Founded in 2017, MAbSilico is a software editor with the vision to accelerate the development of therapeutic antibody focusing on the early stage development to provide leads in a few years today to a few weeks.
MAbSilico is developing a software suite combining algorithms and databases based on 20 years of proven research and protected by patent. Our Artificial Intelligence and machine learning -driven tools cover two key steps of the early-stage antibody development; the lead identification and the lead characterization.
No products posted yet
No services posted yet
This data is part of our proprietary analytics report:
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality